T he microvascular decompression (MVD) procedure has been shown to be an effective and reliable procedure to treat patients with trigeminal neuralgia (TN). 4 The technique has been honed in thousands of patients and is relatively safe with combined stroke and death rates of less than 0.3%. 30 Improvements on the microscopic technique are therefore difficult to demonstrate. Endoscopic MVD (E-MVD) is a relatively new modification of the MVD procedure and has been performed as both an endoscope-assisted approach 6, 10, 18, 33, 34, 38, 44 and as , an 11-point scale that measures pain intensity, interference with general activities of daily living (ADLs), and facial-specific ADLs. Using a standardized script, independent research assistants conducted follow-up telephone interviews. RESULTS In total, 167 patients were available for follow-ups (66.5% female; 93 patients underwent M-MVD and 74 underwent E-MVD). Preoperative characteristics (i.e., TN classification, PFPS components, and medication use) were similar for the 2 surgical groups except for 2 variables. Patients in the M-MVD group had slightly higher incidence of V3 pain, and the 2 groups differed in the date of surgery and hence in the length of follow-up (2.4 years for the M-MVD group and 1.3 years for the E-MVD group, p < 0.05). There was a trend toward not finding neurovascular conflict at the time of surgery more frequently in the M-MVD than in the E-MVD group (11% vs 7%, p = 0.052). Internal neurolysis was more often performed in the E-MVD group (26% vs 7%, p = 0.001). The 2 groups did not significantly differ in the length of the MVD procedure (approximately 2 hours). Self-reported headaches at 1 month postoperatively were present in 21% of the patients in the M-MVD group versus 7% in the E-MVD group (p = 0.01). Pain outcomes at the most recent followup were equivalent, with patients reporting a 5-to 6-point (70%-80%) improvement in pain intensity, a 5-point (85%) improvement in pain interference with ADLs, and a 6-point (85%) improvement in interference with facial-specific ADLs. Actuarial freedom from pain recurrence was equivalent in the 2 groups, with 80% pain control at 3 years. CONCLUSIONS Both the fully endoscopic MVD and the conventional M-MVD appear to provide patients with equivalent pain outcomes. Complication rates were also similar between the groups, with the exception of the rate of headaches, which was significantly lower in the E-MVD group 1 month postoperatively.
a fully endoscopic procedure. 3, 5, 13, 19, 22, 41, 47 A direct comparison of E-MVD with microscopic MVD (M-MVD) involving validated outcome tools such as the Penn Facial Pain Scale (PFPS, formerly known as Brief Pain Inventory [BPI]-Facial) has not been reported. 9, 24, 39 This study is the first direct comparison of bimanual microdissection techniques using either an endoscope or a microscope and involving modern pain-outcome assessment tools.
Methods

Study Design
The present investigation was a single-center, singlesurgeon (J.Y.K.L.), institutional review board-approved retrospective study. On the basis of Burchiel's classification scheme and of the International Headache Society definition of TN, we assigned patients to diagnostic categories. 7, 16 Only the patient's clinical history and classification of TN were used to determine appropriateness for surgery. MRI results were used only to exclude tumors, arteriovenous malformations, and other structural abnormalities, and the presence of neurovascular conflicts (NVCs) on MRI scans was not a criterion to determine appropriateness for surgery. Patients with either Burchiel Type 1 or Burchiel Type 2 TN were offered 1 of 3 procedures: MVD, percutaneous glycerol rhizotomy, or Gamma Knife radiosurgery. The results in the present study represent only those from a subset of patients who chose to undergo MVD.
Surgical Procedures
The surgeon performed 93 M-MVDs between 2006 and 2010. Thereafter, the surgeon transitioned from microscopic surgery to fully endoscopic surgery, which consisted of 14 endoscope-assisted operations in which the microscope was used as the primary visualization tool, and the endoscope was used as an adjunct to further visualize anatomy. 13, 22 Eventually, the microscope was no longer used, and a fully endoscopic surgery was employed. For purposes of analysis, the 14 endoscope-assisted procedures were included in the endoscopic arm for a total of 74 E-MVDs performed between 2010 and 2013. Most importantly, the E-MVDs involved the use of a pneumatic endoscope-holding arm, allowing the surgeon to work with both hands (Fig. 1) . Further details of the technique have been described in previous studies. 5, 13, 22 All cases from these previous reports on E-MVD are included in this series.
Briefly, the patient is placed in a lateral decubitus position, and a linear incision is made behind the ear. In all reported cases, a craniectomy was performed with a drill and Kerrison rongeurs. After the sigmoid and transverse sinuses are identified, a C-shaped dural opening is created and flapped toward the sigmoid sinus (Fig. 2B) . For E-MVD, the pneumatic arm is used to hold the endoscope, while bimanual dissection is performed underneath the 2.7-mm (outer diameter) endoscope. Careful attention is paid to keeping both a distal and proximal triangle to avoid clashing instruments as they are introduced into the cerebellopontine angle. The endoscope is always kept at the apex of the equilateral triangle ( Fig.  2A) . Bimanual dissection is generally preferred, but in cases with a very prominent petrous tubercle, the senior surgeon sometimes resorted to 1-handed surgery to fit both the endoscope and a microdissection instrument into the tight confines of the cerebellopontine angle. In both E-MVD and M-MVD cases, dural closure was done primarily with silk sutures, with adjunct use of a dural collagen allograft. Bony closure was achieved with a titanium mesh plate (Synthes) cut to fit the bony defect for M-MVD procedures and, alternatively, with a bur hole cap for E-MVD cases (Fig. 2C) .
Outcome Assessments
At the first clinic visit, patients completed an extensive questionnaire that included the PFPS (see Appendix). 9, 24 The PFPS measures 3 domains of pain: pain intensity, interference with activities of daily living (ADLs), and interference with facial function.
9,24 An 11-point Likert scale (ranging from 0 to 10) is used to measure these domains. Follow-up phone calls were conducted by independent research assistants, using a standardized telephone script to achieve uniform outcome measures, and included a repeat PFPS assessment, in addition to the use of the Patient Global Impression of Change instrument, a 7-point ordinal scale consisting of the following ratings: "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," and "very much worse." Additional questions concerned outcomes: "When did pain return to the preoperative level?" "Do you have headaches?" "Do you have dizziness?" The responses to these questions were entered into a database (Access, Microsoft Corp.), and exported to an Excel spreadsheet and imported for statistical analysis (STATA version 10, StataCorp LP).
Statistical Analysis
Two-tailed t-tests were used for continuous variables and chi-square tests for categorical variables. Actuarial analysis was performed with Kaplan-Meier techniques, and comparisons of pain recurrence curves were performed with the Cox model. In calculating pain recurrence, we asked patients "When did you experience your facial pain return?" The response was coded in years and months. Hence, any recurrence of facial pain at any time point was considered a "failure" for the purposes of the Cox regression analysis. We believed this to be a more stringent standard than pain scales such as the Barrow Neurological Institute (BNI) pain scale. 35 
Results
Patient Characteristics
Patient demographics were well balanced between the E-MVD and M-MVD groups (Table 1) . Overall, most of the patients in the present study were women (66.5%), and their mean age was in the fifth decade of life. There was a trend toward more patients in the M-MVD group having Burchiel Type 1 TN (88% vs 79%, p = 0.11), a difference that could have biased the results toward better outcomes in the M-MVD group. 32 The distribution of pain along the 3 branches of the trigeminal nerve was similar between the 2 groups, with overall a higher prevalence of V2 and V3 pain than of V1 pain. Curiously, there was a higher proportion of V3 pain in the M-MVD group than in the E-MVD group (71% vs 56%, p = 0.04). In both groups, slightly more patients had right-sided pain than left-sided pain.
There was a trend toward the M-MVD group having undergone more previous procedures (including stereotactic radiosurgery and percutaneous injections, including sphenopalatine blocks) than the E-MVD group (36% vs 24%; p = 0.13). Most patients (> 80%) had been successfully treated with antiepileptic medications (carbamazepine or oxcarbazepine) in the past, but only approximately 40% of patients continued to benefit from these medications at the time of surgery. In all 3 domains of the PFPS, the 2 groups were equally balanced with severe intensity and severe interference: pain intensity had a mean score of 8 at its worst, interfered with general ADLs with a mean score of 6, and interfered with facial function with a mean score of 7. No statistically significant differences were observed in intraoperative findings of vessel compression between the 2 groups ( Table 2 ). We noted a trend toward a higher incidence of nerve compression by the superior cerebellar artery in the M-MVD group (66% vs 51%; p = 0.053). The E-MVD group was less likely to have no vessel identified as a source of the compression, but this difference (7% vs 11%) was not statistically significant (p = 0.052). The 2 groups differed in dates of surgery, and therefore the M-MVD group had a longer length of follow-up (2.4 vs 1.3 years, p < 0.05). Both duration of the procedure (just above 2 hours) and hospital length of stay (approximately 2.5 days) did not differ between the 2 groups.
Complication Rates
Complication rates were very low, and no deaths occurred in either group (Table 3) . No cases complicated by cardiac morbidity, stroke, or hemiparesis were observed in the E-MVD group, and we noted only a slightly higher incidence of some of these major complications in the M-MVD group. The only statistically significant difference between the groups was in the incidence of headaches at the 1-month follow-up: 21% of the M-MVD patients versus 7% of the E-MVD patients reported headaches (p = 0.01). This finding was not anticipated, and data regarding the intensity, character, or duration of the headaches were not available.
The M-MVD group had 2 complications that warrant attention. One patient had a postoperative stroke. This stroke was associated with a petrosal vein tear followed by bipolar coagulation of the vein and inadvertent coagulation of an adjacent pial artery. The stroke was identified when the patient reported gait ataxia, and a small infarct was found on diffusion-weighted MRI scans. Another patient underwent an uncomplicated M-MVD and immediately after surgery was noted to have facial paralysis that failed to resolve with time. For this patient, no changes in brainstem auditory evoked responses were observed during the surgery, and no specific cause of the facial palsy could be identified.
Notably, no statistically significant difference was observed in the incidence of new facial numbness, in spite of the more extensive use of internal neurolysis in the E-MVD group than in the M-MVD group (26% vs 7%, p = 0.001). Internal neurolysis is a technique typically used in the absence of NVC and involves the use of a round knife to dissect between the fascicles of the trigeminal nerve. 20 Before adoption of this technique in 2009, 29 the surgeon would perform a partial sensory rhizotomy only rarely. 12 Within both E-MVD and M-MVD groups, no statistically significant differences in pain outcomes, assessed with the PFPS, were detected between patients who underwent neurolysis and those who did not (p > 0.05). Likewise, no significant difference was detected in univariate Cox regression within each interventional group and with neurolysis as the independent variable (p = 0.15).
Outcomes
At mean follow-up lengths of 2.4 and 1.3 years for the M-MVD and E-MVD groups, respectively, no statistically significant differences were observed in pain outcomes measured with the PFPS (Table 4) . Patients improved by 5-6 points (70%-80%) in the domain of pain intensity, 5 points (85%) with respect to interference with ADLs, and 6 points (85%) for interference with facial function. These findings were validated by the Patient Global Impression of Change measure: no statistically significant difference was detected in the proportion of patients who reported "very much improved" or "much improved" in the 2 groups. Approximately 25% of the patients remained on medications postoperatively. However, medications were broadly defined as any neuropathic pain medication that could have been used for a variety of indications (e.g., gabapentin for lumbar radiculopathy) and not specifically for TN. Last, using the Cox model, we did not detect a statistically significant difference between the 2 groups in actuarial freedom from facial pain recurrence, and we observed 80% pain control at 3 years (Fig. 3) .
Discussion
Microvascular decompression involving a microscope for magnification and visualization is a standard of care for patients with medication-refractory TN. 4 The use of the endoscope for MVD, however, remains a niche technique used by only a few surgeons. 5, 13, 19, 22, 41 Indeed, most studies report using a hybrid technique that we refer to as endoscope-assisted MVD, 33, 34, 44 in which the angled endoscope is used primarily as an adjunct to the microscope in examining local anatomy. The only study directly comparing M-MVD and E-MVD merely reported raw differences. 19 Hence, the current investigation is the first to compare these 2 techniques with standard statistical methods and to use a reliable and validated outcome tool, the PFPS (formerly known as BPI-Facial).
9,24,39
Outcome Tools in TN Assessment
In the absence of randomized clinical trials to provide evidence for decision making in the surgical management of TN, it is imperative to document outcomes after TN surgery in a systematic manner. Trigeminal neuralgia is a chronic pain condition; hence, the primary outcome variable is pain, ideally assessed as both its sensory (pain intensity) and reactive components (interference with daily life) in accordance with the consensus guidelines of pain study group initiatives such as the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). 46 In a 2003 review, however, the authors note that of 222 articles, only 1 measured pain before surgical intervention, precluding analysis of the impact of the intervention on pain. 48 A more recent review of articles spanning the 2008-2010 period reported that only 13 studies of 56 used outcome measures.
1 All but 2 of these studies used the BNI pain scale, 35 which has been widely adopted because of its perceived simplicity of use, but has never been validated. Moreover, the BNI scale is a composite of 3 outcome variables (intensity of pain, medica- which was originally developed for cancer-specific pain and is currently widely used for a variety of pain etiologies. 11, 43 Although the BPI measures both the sensory and reactive components of pain, it does not cover symptoms specific to TN.
In 2010, the senior author of the present study (J.Y.K.L.) modified the BPI to create the PFPS and validated its use in the population of patients with TN. 24 The PFPS measures 3 domains of pain (intensity, interference with general ADLs, and interference with facial-specific ADLs) and was shown to have reliable internal consistency. The minimum clinically important difference in pain outcomes for TN patients undergoing surgical intervention has also been defined for the PFPS. 39 Researchers in another study used the PFPS to detect subtle differences in outcomes depending on the dose rate in Gamma Knife radiosurgery for TN 25 and for which previous outcome tools such as the BNI scale may not have been sensitive enough. 2 The PFPS has recently been endorsed by Zakrzewska and colleagues as the "essential outcome measure" for the systematic study of pain in patients with TN. 1 Given these benefits, we employed the PFPS in the current study with the goal of determining whether E-MVD would lead to better outcomes than M-MVD. We report our findings in close adherence to the Surgical TN Score. 
Endoscopic Microvascular Decompression
In the present study, pain outcomes were measured before and after surgery with the validated PFPS. At baseline, the patients in the M-MVD and E-EVD groups were well matched in all 3 dimensions of the PFPS. The patients in both groups exhibited an improvement of 70%-80% in pain intensity, interference with general ADLs, and facialspecific ADLs. In addition, medication use dropped from approximately 80% to 20%. No statistically significant differences in these outcomes were detected between the 2 groups; hence, our results indicate similar efficacy of MVD regardless of whether a microscope or endoscope was used. Likewise, actuarial freedom from severe pain recurrence was equivalent, with 80% pain control at the 3-year follow-up for both groups.
The use of the endoscope for visualization and magnification resulted in higher rates of identification of NVC (Fig. 4) . In up to 28% of cases, the offending vessels can be identified only with the panoramic view afforded by the endoscope. 6, 10, 18, 38, 44 Whether this improved visualization improves outcomes in TN surgery has not been studied. In the present study, NVC could not be visualized in 11% of M-MVDs and 7% of E-MVDs, a difference that trended toward statistical significance. In spite of this trend toward improved visualization of NVC with the use of an endoscope, no difference in pain outcomes was observed between the 2 procedures.
One possible explanation, proposed by Burchiel, why improved visualization of NVC, and presumably higher rates of decompression, may not lead to better pain outcomes is that trigeminal NVC may not be necessary or sufficient for causing TN. Both Type 1 and 2 TNs have been shown to occur or reoccur without MRI evidence of neurovascular compression in 29% and 18% of cases, respectively. 23 Moreover, MRI evidence of neurovascular compression was reported in 17% of trigeminal nerves in individuals without symptoms of TN. Use of endoscopic techniques in MVD can shed further light on these fascinating investigations. For a subset of patients who underwent surgical exploration, Lee et al. reported that the sensitivity of MRI for predicting NVC visualized with the microscope was 96% for both Type 1 and 2 TNs, and the specificity was 90% and 66%, respectively. 23 The use of the endoscope, that is, higher rates of NVC visualization than with the microscope, would most likely decrease the number of false-negative NVCs on MRI scans, that is, decrease the specificity of MRI. In other words, use of an endoscope in TN surgery could show that the rates of NVC are actually higher than those reported by Lee et al. 23 Moreover, internal neurolysis is typically performed only in the absence of NVC. 20 Hence, improved visualization of the cerebellopontine angle with the endoscope allows the surgeon to more confidently rule out NVC, thereby aiding surgical decision making.
The results of the present study show that primary outcomes after E-MVD are not inferior to those of the more established M-MVD. As discussed, E-MVD also has the benefit of improved visualization of the cerebellopontine angle (Fig. 4) , in addition to theoretically allowing for a smaller bony exposure and dural opening (Fig. 2B) . Its disadvantages include a 2D view lacking a depth of field, the endoscope itself occupying space within a small surgical area, and heat generation at the tip of the endoscope that could potentially harm adjacent structures.
Postoperative Headaches
Postoperative headaches are a well-recognized complication after surgery via a retrosigmoid approach, which results in a higher incidence of these adverse effects than with other approaches. 21 In a large series of 318 M-MVD patients, the rate of headaches 1 month postoperatively was 28.8%, 28 which is similar to the 21% incidence observed among patients in our M-MVD group.
Interestingly, the incidence of postoperative headaches at 1 month postoperatively was lower in the E-MVD group, at 7% versus 21% in the M-MVD group. Previous E-MVD case series have not examined postoperative headaches. 3, 19, 41, 47 Because the present study was not designed to more closely investigate the incidence of postoperative headaches, we did not have information about their intensity, character, or duration. However, it is clear from the existing literature on retrosigmoid approaches that the headache incidence is highest immediately after the surgery and gradually improves over time (Table 5) ; therefore, it is safe to assume that headaches will gradually resolve over time in both groups.
Possible etiologies of postoperative headaches after surgery involving a retrosigmoid approach include adherence of scalp and muscles to the dura, aseptic meningitis from bone dust, injury to occipital nerves, and neck spasms. 8 In the current series, all patients underwent titanium cranioplasty either with a 15/17-mm bur hole cap in patients in the E-MVD group (Fig. 2C) or with a larger mesh plate that was cut and contoured to fit the bony defect in patients in the M-MVD group. Hence, one possible explanation for our finding is the size of the bony exposure in combination with a larger scalp incision and muscle dissection that may have increased the likelihood of injury to the occipital nerves and of postoperative neck spasms. Indeed, in a study primarily comparing the incidence of postoperative headaches between patients who underwent craniotomy or craniectomy for a retrosigmoid approach, the authors found that the greatest predictor of headaches in craniotomy patients is the size of the bone flap. 45 Using logistic regression, we calculated an odds ratio of 7.5 in favor of a smaller flap (< 3 cm) over a larger flap (3-6 cm) for reducing the risk for headaches.
Study Limitations
Although the PFPS is patient scored and was prospectively administered, the design of the present study was retrospective and nonblinded. The patient sample represented the practice of a single neurosurgeon at a tertiary referral center and therefore may lack generalizability to other practice settings. Longitudinal data were acquired at the 1-month follow-up, but during the subsequent period, the follow-up intervals were not standardized. A better study design would have mandated phone calls at serial time points after surgery, such as at yearly intervals. Last, postoperative headaches were assessed only at the 1-month follow-up.
Conclusions
The Penn Facial Pain Scale, a novel, quantitative, and validated outcome tool was employed to assess whether patients with TN statistically significantly differed in pain outcomes after E-MVD or conventional M-MVD performed by the same surgeon. The results of the PFPS assessment and Kaplan-Meier techniques did not indicate any significant differences in TN pain outcomes between the 2 MVD groups. Endoscope use, however, did result in a statistically significant decrease in the incidence of headaches 1 month after surgery, suggesting that use of E-MVD may be favorable for patients in the hands of appropriately trained surgeons. All other complications were indistinguishable between the 2 groups. The explanation for the lower incidence of headaches with E-MVD is likely multifactorial and could have resulted from a smaller bony exposure, muscle dissection, and scalp incision. Future studies could explore these possible explanations for decreased postoperative headaches with E-MVD.
